Elan gets ‘outperform’ rating

ELAN was given an “outperform” rating by Credit Suisse and added to the bank’s “Focus List” on optimism about sales of the Tysabri multiple sclerosis medicine and an Alzheimer’s drug.

The Alzheimer’s treatment, dubbed AAB-001, holds “multi- billion dollar potential,” analysts said. Sales of Tysabri could rise to $2 billion (€1.3bn) over the next three years, they said.